Prostate cancer (PCa) remains a disease of high incidence, but orphan of a specific screening program. For this
reason, non-invasive techniques capable to predict PCa in patients with high specificity and sensitivity are still an
urgent need. One of the major goals is to improve the PCa diagnosis and the identification of patients who benefit
from tissue biopsies. Another need is the necessity to have novel biomarkers to better stratify the risk of patients
with PCa to predict the aggressiveness of the tumor and the overall survival. Liquid biopsy can be an important
non-invasive tool to stratify PCa at the molecular level to improve diagnosis and prognosis, and, possibly, to
develop screening programs and follow-up. With this review, we are reporting the lastest update of aberrant
methylation detection on circulating tumor DNA as a tool to improve prostate cancer diagnosis and prognosis.
